GB-4362

· Generate Biomedicines

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GB-4362, covering 2026-04-07 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer [Phase 1]